Summary
Medtronic plc (MDT) filed its 10-K for the fiscal year ending April 27, 2023, reporting total net sales of $31.2 billion. While overall sales saw a slight decrease of 1% compared to the prior year, this was largely attributed to unfavorable currency impacts, particularly in developed markets, and ongoing supply chain challenges. The company's strategic focus remains on leveraging its pipeline, accelerating innovation, and improving operational nimbleness across its four key segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. Despite the slight top-line dip, Medtronic highlighted growth in key areas such as Micra transcatheter pacing systems, transcatheter aortic valve replacements (TAVR), and neurovascular therapies. The company also reported progress in its ESG initiatives and a strong commitment to employee development and an inclusive workplace. Management anticipates continued focus on innovation and market expansion, particularly in emerging markets, while navigating macroeconomic headwinds such as inflation, rising interest rates, and geopolitical factors.
Financial Highlights
55 data points| Revenue | $31.23B |
| Cost of Revenue | $10.72B |
| Gross Profit | $20.51B |
| SG&A Expenses | $10.41B |
| Operating Income | $5.49B |
| Interest Expense | $636.00M |
| Net Income | $3.76B |
| EPS (Basic) | $2.83 |
| EPS (Diluted) | $2.82 |
| Shares Outstanding (Basic) | 1.33B |
| Shares Outstanding (Diluted) | 1.33B |
Key Highlights
- 1Total net sales for fiscal year 2023 were $31.2 billion, a 1% decrease from fiscal year 2022, primarily due to unfavorable currency impacts and supply chain challenges.
- 2The Cardiovascular segment showed growth, with net sales increasing 1% to $11.6 billion, driven by strong performance in Micra pacing systems and TAVR, partially offset by currency headwinds.
- 3The Medical Surgical Portfolio experienced an 8% decline in net sales to $8.4 billion, impacted by reduced ventilator demand compared to the prior year and supply chain issues.
- 4The Neuroscience Portfolio saw a 2% increase in net sales to $9.0 billion, driven by growth in spine, neurovascular, and ENT products, with acquisitions contributing positively.
- 5The Diabetes Operating Unit's net sales decreased by 3% to $2.3 billion, primarily due to unfavorable currency impacts and domestic market challenges, though international growth for the MiniMed 780G system showed promise.
- 6Medtronic reported $4.6 billion in free cash flow for fiscal year 2023.
- 7The company continued its share repurchase program, with approximately $2.4 billion remaining under the authorized program as of April 28, 2023, and announced an increase in its quarterly cash dividend.